Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Rhea-AI Summary

Kronos Bio, Inc. (Nasdaq: KRON) announced the participation of key executives in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference. The event will be held on December 6, 2023, at 11:00 a.m. ET, with a live audio webcast available on the company's website. The participation of Dr. Jorge DiMartino and Dr. Charles Lin signifies the company's commitment to advancing precision oncology.

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN mapping will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023 at 11:00 a.m. ET.

A live audio webcast of the event will be available on the Investors and Media section of the Kronos Bio website at www.kronosbio.com. A replay of the webcast will be available for 30 days following the event.

About Kronos Bio, Inc.

Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer. The Company is developing the CDK9 inhibitor KB-0742 as a treatment for MYC-amplified solid tumors and other transcriptionally addicted solid tumors and lanraplenib, a next-generation SYK inhibitor, for patients with FLT3-mutated acute myeloid leukemia. The Company also has a maturing discovery pipeline from which they are on track to announce a development candidate in early 2024 for their IRF4 modulator program for use in multiple myeloma. The Company’s scientific focus is on developing medicines that target the deregulated transcription that is the hallmark of cancer and other serious diseases.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com/ or follow the Company on LinkedIn.

Media Contact:
Sarah Connors
Vice President of Corporate Affairs, Kronos Bio
857-290-7305
sconnors@kronosbio.com

Investor Contact:
Margaux Bennett
Executive Director, Business Development and Investor Relations, Kronos Bio
650-781-5026
mbennett@kronosbio.com

 

FAQ

What is the latest announcement from Kronos Bio, Inc. (Nasdaq: KRON)?

Kronos Bio, Inc. (Nasdaq: KRON) announced the participation of key executives in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference.

When and where will the event take place?

The event will be held on December 6, 2023, at 11:00 a.m. ET. A live audio webcast of the event will be available on the Investors and Media section of the Kronos Bio website at www.kronosbio.com.

Who will be participating in the fireside chat?

Dr. Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN mapping will participate in the fireside chat.

Where can I access the webcast?

A live audio webcast of the event will be available on the Investors and Media section of the Kronos Bio website at www.kronosbio.com.

Will there be a replay of the webcast available?

A replay of the webcast will be available for 30 days following the event.